Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Maze Therapeutics Inc (NASDAQ: MAZE) closed the day trading at $27.0 up 2.47% from the previous closing price of $26.35. In other words, the price has increased by $2.47 from its previous closing price. On the day, 0.6 million shares were traded. MAZE stock price reached its highest trading level at $28.33 during the session, while it also had its lowest trading level at $26.04.
Ratios:
For a better understanding of MAZE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.63 and its Current Ratio is at 13.63. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, BTIG Research on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On July 23, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $34.
On July 08, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $17.Wedbush initiated its Outperform rating on July 08, 2025, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 ’25 when SCHELLER RICHARD H sold 20,744 shares for $22.37 per share. The transaction valued at 464,035 led to the insider holds 0 shares of the business.
RICHARD SCHELLER bought 20,744 shares of MAZE for $464,035 on Sep 15 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MAZE now has a Market Capitalization of 1183973888 and an Enterprise Value of 944441856. For the stock, the TTM Price-to-Sale (P/S) ratio is 473.59 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 377.777 whereas that against EBITDA is -7.678.
Stock Price History:
Over the past 52 weeks, MAZE has reached a high of $27.67, while it has fallen to a 52-week low of $6.71. The 50-Day Moving Average of the stock is 57.67%, while the 200-Day Moving Average is calculated to be 105.51%.
Shares Statistics:
Over the past 3-months, MAZE traded about 401.49K shares per day on average, while over the past 10 days, MAZE traded about 781970 shares per day. A total of 43.85M shares are outstanding, with a floating share count of 19.56M. Insiders hold about 55.40% of the company’s shares, while institutions hold 35.40% stake in the company. Shares short for MAZE as of 1757894400 were 1634122 with a Short Ratio of 4.07, compared to 1755216000 on 1777795. Therefore, it implies a Short% of Shares Outstanding of 1634122 and a Short% of Float of 4.5500003.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4 analysts currently analyzing and rating the stock of Maze Therapeutics Inc (MAZE).The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.64 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$3.11 and -$3.24 for the fiscal current year, implying an average EPS of -$3.17. EPS for the following year is -$2.82, with 4.0 analysts recommending between -$2.53 and -$3.22.
